Building a First-in-Class CXCR5-Targeting Cell Therapy to Overcome Relapse Through Dual Tumour & Microenvironment Targeting
9:45 am - Wednesday 10th February 2027
- Harnessing CXCR5 as a novel therapeutic target to address antigen escape while targeting tumorigenic cells and the tumour microenvironment
- Demonstrating the scientific rationale for CXCR5-directed therapies, including the elimination of both malignant B-cells and CXCR5-expressing TFH cells that contribute to disease persistence
- Sharing the latest preclinical progress across oncology and autoimmune indications and looking to the future for clinical development
